International › Status 2025 · Last reviewed 2026-05-16

Worldwide status 2025

Summary

Jurisdictions diverge in their treatment of the Dutch Protocol. In Sweden, Socialstyrelsen gave a weak negative recommendation in December 2022 and allows treatment of minors only in exceptional cases, preferably within research (source); according to the Cass Review the Finnish guideline proposes extreme caution with puberty blockers under 18 and, like the Swedish one, recommends puberty suppression under a research protocol (source); in the United Kingdom NHS England has set out that puberty blockers are only available under a research protocol; in Norway the Ukom committee recommended defining these treatments as experimental treatment (source). The Netherlands has kept its approach: in June 2026 the Dutch Health Council saw no reason to organise the care differently, while calling the evidence of low to very low certainty (source).

Overview by country

CountryPolicy 2025Source / body
NetherlandsContinuation; the Health Council (30 June 2026) sees no reason to organise the care differently, notes low to very low certainty of evidence and calls for more researchGezondheidsraad advice 2026/12
United KingdomPuberty blockers only under a research protocol (NHS England, as described in the Cass Review)Cass Review 2024, par. 160
SwedenSocialstyrelsen (December 2022): weak negative recommendation; treatment only in exceptional cases, preferably within researchSocialstyrelsen 2022; SBU 2022
FinlandPsychosocial care first-line; extreme caution with puberty blockers under 18 (as summarised by the Cass Review)COHERE 2020
NorwayUkom (March 2023) recommended defining these treatments as experimental treatment (utprøvende behandling)Ukom 2023
US — federalHHS published a review of the evidence in 2025 (Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices); WPATH and USPATH published a joint response on 2 May 2025HHS; WPATH/USPATH

Critical note

In its appraisal of international guidelines, the research team for the Cass Review could recommend only two for practice: the Finnish guideline of 2020 and the Swedish guideline of 2022 (source). The Netherlands has taken a different course: the advice of the Dutch Health Council of 30 June 2026 concludes that the intended physical effects are achieved and that there are indications of some improvement in mental outcomes, but also that the certainty of the evidence is low to very low and that effects on cognition and fertility and long-term effects are insufficiently studied. The committee sees no reason to recommend organising the care differently and advises anchoring the diligence requirements more firmly in the revised quality standard (source).1

See also

Footnotes

  1. Gezondheidsraad. Transgenderzorg voor jongeren. Advies nr. 2026/12; 30 June 2026.